The Dow Jones Industrial Average fell on Tuesday as the Federal Reserve kicked off a two-day monetary policy meeting.US Marketsread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
Facebook has partnered with Ray-Ban maker Luxottica to develop augmented-reality glasses, people familiar with the matter told CNBC. The glasses, code-named 'Orion,' are being...Technologyread more
As Netflix's rivals prep for their own streaming service launches, and snatch up content belonging to their own networks, Netflix could soon face a dry well when it comes to...Entertainmentread more
"There's a huge reorganization going on in China regarding fentanyl to try to shut it down," Blackstone co-founder Stephen Schwarzman says.Health and Scienceread more
The fallout from two fatal crashes of Boeing 737 Max planes has ensnared the manufacturer's most-loyal customer: Southwest Airlines. The carrier has canceled thousands of...Airlinesread more
Pelosi also said it's "irrelevant" whether approving the USMCA trade deal would give President Donald Trump a victory ahead of the 2020 election.Politicsread more
The fine against Carmene "Zsa Zsa" DePaolo was the maximum possible civil penalty that she faced under the Hatch Act for her comments about Hillary Clinton's immigration plan...Politicsread more
Sen. Elizabeth Warren has called on lobbyists to be banned from donating and fundraising for their preferred campaigns. Her new plan represents the latest shift for Warren who...2020 Electionsread more
Half of Saudi Arabia's crude production cut during Saturday's attack has been restored in the past two days, the kingdom's energy minister said Tuesday.Oilread more
General Motors stands to lose hundreds of millions of dollars in lost production as a United Auto Workers union strike against the automaker enters its second day, but Wall...Autosread more
Shares of Sage Therapeutics soared 70 percent on Thursday after the company announced positive results in the testing a major depressive disorder (MDD) treatment.
Sage said in a release that 64 percent of patients achieved MDD remission using the SAGE-217 drug in the 15th day of treatment.
This is the second successful drug trial result in as many months for Sage. On Nov. 9, the company said brexanolone — a drug aimed at treating moderate and severe postpartum depression — met its main goal in two late-stage studies. The stock shot up 54.2 percent that day and is up 44.1 percent over the past month.
"These very encouraging data suggest the potential of SAGE-217 in the treatment of MDD as well as other mood-related disorders that we may pursue," CEO Jeff Jonas said in a statement. "The positive activity and safety findings of SAGE-217 in MDD support advancing the program into later stage clinical development."